Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
LaggingIntellia Therapeutics, Inc. (“we,” “us,” “our,” “Intellia,” or the “Company”) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. Our mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, we aim to reset the standard for medicine by durably treating the root causes of disease.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Q1 2023 · $40.8MThe company’s own SEC segment disclosure.
- Research And Development Services$40.7M100%
- Research Materials Shippmet Services$100.0K0%
Intellia Therapeutics, Inc. (NTLA) reported revenue of $15M in Q1 2026 (quarter ended Mar 31, 2026), down 9.5% from the same quarter a year earlier. That came with net loss of $96M. For the full year FY2025, revenue was $68M (+17% year on year) and net income −$413M. Its largest product in Q1 2023 (quarter ended Mar 31, 2023) was Research And Development Services at $41M, 100% of the disclosed total, well ahead of Research Materials Shippmet Services at 0.2%.
Raw charts
9 series · TTMAs reported to the SEC, without any scoring.